Rocket Pharmaceuticals, Inc.
NASDAQ:RCKTBiotechnology
+$0.06 today
- Market cap
- $235.60M
- Beta
- 0.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$1.87
Volume 1.79M
Average 3.15M
Returns on capital
Rocket Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-80.5%
avg -49.6%
ROIC
-75.4%
avg -37.8%
ROA
-67.5%
avg -39.4%
Analysis
ROA is currently the strongest return metric at -67.5% versus its period average of -39.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Gaurav D. Shah | Chief Executive Officer & Director | USD 1.09M | 51 | — | — |
Martin Louis Wilson | Gen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corporation Officer | USD 767.47K | 50 | — | — |
Jonathan Schwartz | Chief Science & Gene Therapy Officer | USD 614.33K | 62 | — | — |
Christopher Stevens | Chief Operating Officer | USD 604.47K | 46 | — | — |
Kevin Giordano | Director of Corporate Communications | — | — | — | — |
Joseph Manhede | Principal Accounting Officer | — | 48 | 52.58K | 0.05% |
Sarbani Chaudhuri | Chief Commercial Officer | — | 51 | 257.94K | 0.24% |
Syed Ali-Aamir Rizvi | Chief Medical Officer | — | 59 | 93.04K | 0.09% |
Meg Dodge | Senior Vice President & Head of External Affairs | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 9, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$34,400.00
Sells
27
$1.00M
Net Transaction Value
−$968,754.84
Net selling
Most Active
Wilson Martin
9 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 9, 26Nov 9, 2026 | Chaudhuri Sarbani Direct | Sell | $11.3K$11,337.14 |
| Nov 5, 26Nov 5, 2026 | Wilson Martin Direct | Sell | $127.8K$127,813.27 |
| Sep 11, 26Sep 11, 2026 | Wilson Martin Direct | Sell | $256.5K$256,463.69 |
| Aug 18, 26Aug 18, 2026 | Wilson Martin Direct | Sell | $2.1K$2,133.41 |
| Aug 18, 26Aug 18, 2026 | Shah Gaurav Direct | Sell | $7.8K$7,752.63 |
| Aug 13, 26Aug 13, 2026 | Shah Gaurav Direct | Sell | $9.6K$9,591.90 |
| Aug 13, 26Aug 13, 2026 | Wilson Martin Direct | Sell | $11.8K$11,809.83 |
| Aug 11, 26Aug 11, 2026 | Stevens Christopher James Direct | Sell | $128.3K$128,266.34 |
| Aug 11, 26Aug 11, 2026 | Chaudhuri Sarbani Direct | Sell | $16.4K$16,448.80 |
| May 21, 26May 21, 2026 | Shah Gaurav Direct | Sell | $171.8K$171,840.82 |
1–10 of 28
Summary
Insiders reported 1 buys worth $34,400.00 and 27 sells worth $1.00M over the last 12 months. That adds up to net selling of $968,754.84. Wilson Martin was the most active insider with 9 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Rocket Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about RCKT's management, answered from reported figures.
Who manages RCKT?
Rocket Pharmaceuticals, Inc. (RCKT) lists 9 active executives. The top listed executive is Kevin Giordano, Director of Corporate Communications.
Are RCKT insiders buying or selling?
Recent insider activity shows net buying of $59.37M.
Continue the stock analysis
Jump to another research area for this company.